<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>1758-3284-1-S1-O10</ui>
   <ji>1758-3284</ji>
   <fm>
      <dochead>Oral presentation</dochead>
      <bibl>
         <title>
            <p>Ploidy analysis post Sudb&#248; &#8211; where are we now?</p>
         </title>
         <aug>
            <au id="A1" ca="yes">
               <snm>Novelli</snm>
               <fnm>Marco</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Department of Histopathology, University College London, London, UK</p>
            </ins>
         </insg>
         <source>Head &amp; Neck Oncology</source>
         <supplement>
            <title>
               <p>1<sup>st </sup>Scientific Meeting of the Head and Neck Optical Diagnostics Society</p>
            </title>
            <editor>Colin Hopper, Adel K El-Naggar, Tahwinder Upile, Waseem Jerjes and HJCM Sterenborg</editor>
            <sponsor>
               <note>Publication of this supplement was made possible with support from KARL STORZ Endoskope</note>
            </sponsor>
            <note>Meeting abstracts &#8211; A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-3284-1-S1-full.pdf">here</a>.</note>
            <url>http://www.biomedcentral.com/content/pdf/1758-3284-1-S1-info.pdf</url>
         </supplement>
         <conference>
            <title>
               <p>1<sup>st </sup>Scientific Meeting of the Head and Neck Optical Diagnostics Society</p>
            </title>
            <location>London, UK</location>
            <date-range>14 March 2009</date-range>
            <url>http://www.ucl.ac.uk/hnods/Meetings/Meetings/1stScientificMeeting</url>
         </conference>
         <issn>1758-3284</issn>
         <pubdate>2009</pubdate>
         <volume>1</volume>
         <issue>Suppl 1</issue>
         <fpage>O10</fpage>
         <url>http://www.headandneckoncology.org/content/1/S1/O10</url>
         <xrefbib>
            <pubid idtype="doi">10.1186/1758-3284-1-S1-O10</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>28</day>
               <month>7</month>
               <year>2009</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2009</year>
         <collab>Novelli; licensee BioMed Central Ltd.</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>In January 2006 the medical research world was rocked by the discovery that a Norwegian Oncologist, Jon Sudb&#248;, had committed extensive scientific fraud. Four papers in three top medical journals had to be retracted. Two of these papers, both published in the New England Journal of Medicine, described how aneuploidy could be used as a prognostic marker in pre-malignant oral epithelial lesions. There was widespread fallout from this scandal, one of the main casualties being the general reputation of ploidy analysis. However, DNA cytometry research has continued and results suggest that ploidy analysis may well be useful as a screening and prognostic marker in a variety of malignant and pre-malignant conditions. In 2008 Torres-Rendon <it>et al </it>published a further study examining the use ploidy as a prognostic marker in oral epithelial dysplasias. Their results, although not as impressive as Sudb&#248;'s, do suggest that ploidy analysis is a potentially useful prognostic marker in pre-malignant oral epithelial lesions.</p>
      </sec>
   </bdy>
</art>

